Barclays downgraded Medpace (MEDP) to Underweight from Equal Weight with a price target of $425, down from $450. The downgrade is mostly on valuation, as Barclays sees Medpace’s growth deceleration in the second half of 2026 as well as margin pressure, the analyst tells investors in a research note. The firm believes the shares trading at peak multiples on peak earnings growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEDP: